Loading market dashboard
NeuroPace, Inc.
NPCEHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical out.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace's broader AI platform strategy, leveraging the world's only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. ECoG Assistant: Treatment Insights Si.
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
NeuroPace NASDAQ: NPCE raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution across epilepsy treatment centers.
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.21 per share a year ago.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. First Quarter 2026 Highlights Total revenue of $22.1 million in the quarter. Excluding DIXI Medical, total revenue of $22.0 million representing 20.1% year over year growth RNS System revenue of $21.7 million in the quarter, r.
NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS® System Post-Approval Study (PAS) in Neurology, alongside the Company's recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meet.
NeuroPace (NASDAQ: NPCE - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Insider and Institutional Ownership 78.8% of NeuroPace shares
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference at 1:30pm ET (10:30am PT) on Tuesday, April 14, 2026. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty.
Integer (NYSE: ITGR - Get Free Report) and NeuroPace (NASDAQ: NPCE - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends. Insider and Institutional Ownership 99.3% of Integer shares are held
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NeuroPace, Inc. (NASDAQ: NPCE - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and two have given a
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
